Important Safety Information
Clenbuterol is not FDA-approved for human use in the United States. The FDA discontinued approval for human medicinal products containing clenbuterol in 2006. The only FDA-approved product containing clenbuterol is Ventipulmin Syrup, indicated for horses with airway obstruction.
Clenbuterol is a prohibited substance in sport under WADA section S1.2 (Other Anabolic Agents) and is banned at all times. There is no threshold below which clenbuterol is not prohibited. Athletes who test positive may face sanctions, including long-term bans, even if the substance was ingested inadvertently through contaminated meat.
Important
Not for Human Use
This product is sold as a research chemical and is not approved for human use. Products sold online under the name clenbuterol through research compound vendors are not FDA-regulated, have no verified manufacturing standards, and carry unknown contamination, dosing, and safety risks.
Potential Adverse Effects
Clenbuterol is a potent sympathetic stimulant associated with significant cardiovascular adverse effects. Case reports document myocardial injury, myocarditis, and non-ST-segment elevation myocardial infarction in young adults using clenbuterol for weight loss or bodybuilding. A 21-year-old bodybuilder presented with sinus tachycardia, hypokalemia (potassium 3.1 mmol/L), and peak troponin of 863 ng/L after ingesting excessive clenbuterol.
Other commonly reported adverse effects include tachycardia, tremors, hypokalemia, muscle cramps, palpitations, nervousness, headache, and insomnia. Animal studies demonstrate that clenbuterol induces myocyte necrosis in cardiac and skeletal muscle at doses within the range commonly abused by athletes, with a single administration sufficient to induce 3.8% necrosis in the soleus muscle.
Chronic clenbuterol use is associated with beta-2 adrenoceptor desensitization and downregulation, which diminishes its effects over time and may lead users to escalate doses, increasing the risk of toxicity.
Conditions Requiring Medical Evaluation
As clenbuterol is not approved for human use, there are no established contraindications in non-clinical settings. However, individuals with cardiovascular disease, arrhythmias, hypertension, or a history of myocardial infarction should avoid clenbuterol. The cardiotoxic effects observed in case reports and animal studies suggest that anyone with pre-existing cardiac conditions is at elevated risk.
Monitoring During Research Use
No monitoring parameters have been established for clenbuterol outside clinical trial settings. In case reports, cardiac troponin, potassium, and electrocardiogram monitoring were used to assess myocardial injury. Laboratory testing of the product itself, such as the published potency report shown in the Lab Reports tab, is separate from any clinical monitoring. Product testing does not assess individual health status or suitability for use.
Product Care
Storage & Handling
Oral tablets should be stored at controlled room temperature (15–25°C) in the original packaging, protected from excessive heat, moisture, and direct light. Keep out of reach of children.
Clenbuterol hydrochloride is classified as toxic if swallowed. Handle with appropriate precautions and dispose of unused product according to local regulations.